The fund acquired 2.44 million shares of DMRA, now its fifth-largest holding at 8.75% of AUM as of March 31, 2026.
FCPM III Services B.V. disclosed a $65.63 million stake in Damora Therapeutics (NASDAQ:DMRA) after purchasing 2.44 million shares during the first quarter of 2026. The position, valued at $63.22 million at quarter-end, represents 8.75% of the fund’s reportable assets under management as of March 31, 2026.
The acquisition marks a new position for the fund, which holds $294.46 million in NASDAQ:NAMS as its largest asset, followed by stakes in DYN, VOR, ENGN, and MPLT. Damora Therapeutics shares have surged nearly 700% over the past year, closing at $24.88 on Friday.
Damora Therapeutics focuses on developing small-molecule therapeutics for cancer and fibrotic diseases, operating as a clinical-stage biotechnology company.